Investing.com -- Viatris Inc (NASDAQ:VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of Venofer® Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. The medication will be available in single dose vials in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL. The FDA granted Viatris a competitive generic therapy designation for the 100 mg/5 mL and 200 mg/10 mL strengths, which provides expedited review and eligibility for 180 days of market exclusivity upon commercial launch. "The first FDA approval of a generic iron sucrose is an important advancement for patients with CKD and iron deficiency anemia and a testament to Viatris’ advanced technical and manufacturing capabilities," said Philippe Martin, Viatris Chief R&D Officer. The company developed the complex injectable product in-house after working closely with the FDA for several years. Viatris noted that its pipeline includes additional complex injectables across multiple therapeutic areas, including ferric carboxymaltose injection, another iron replacement product. According to IQVIA data cited by Viatris, Venofer® had annual sales of approximately $515 million in the U.S. as of June 30, 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Viatris Inc. (NASDAQ:VTRS) is included among the 13 Best March Dividend Stocks to Buy. On February 27, UBS raised its price recommendation on Viatris Inc. (NASDAQ:VTRS) to $20 from $18.

Kuehn Law is investigating possible breaches of duty by Viatris Inc. officials. Shareholders are urged to contact the firm for potential legal recourse.

Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.

Viatris (NASDAQ:VTRS) reported strong Q2 2025 results, with total revenues of $3.58 billion, down 6% year-over-year but exceeding expectations. The company's adjusted EPS reached $0.62, while adjusted EBITDA was $1.1 billion. Despite challenges, Viatris demonstrated resilience across its global business segments.Key highlights include positive results from five Phase 3 clinical trials and significant capital returns to shareholders totaling $630 million year-to-date, including $350 million in share buybacks. The company reiterated its 2025 financial guidance, expecting to perform in the top half of the range for total revenues and adjusted EPS.Regional performance showed strength in Greater China with 9% growth, while other markets faced some headwinds. The company continues to advance its late-stage pipeline and maintains its commitment to strategic growth initiatives for 2026 and beyond.

Viatris (NASDAQ:VTRS) announced positive top-line results from its VEGA-3 Phase 3 trial for MR-141, a treatment for presbyopia. The randomized, placebo-controlled study involving 545 patients met its primary and all secondary endpoints, demonstrating significant improvement in near vision without compromising distance vision.The trial showed statistically significant results (p<0.0001) in achieving ≥3-line gain in binocular distance-corrected near visual acuity. Patients reported significant functional benefits and satisfaction with near vision improvements, particularly in dim lighting conditions. The safety profile remained consistent with previous trials, with no treatment-related serious adverse events.Viatris plans to submit an FDA application in H2 2025 for MR-141, targeting a condition that affects approximately 90% of U.S. adults over 45.

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant changes.